Background: PD-1-inhibitors play a key role in the treatment of melanoma and other cancers. However, a number of cutaneous adverse events have been reported. Objective: We reviewed the literature on clinical and histological characteristics of PD-1 inhibitor-induced skin reactions, their potential pathogenesis and treatment. Materials and methods: The literature was searched for publications on PD-1 inhibitor induced skin reactions using the MEDLINE and SCOPUS databases. Discussion: Morbilliform, lichenoid, psoriasiform and eczematous skin reactions have been documented to have occurred in the context of PD-1 inhibitor usage. The skin reactions are thought to result from altered immunological tolerance. This response may be heightened in the presence of other immunomodulating agents. Although these skin reactions present diversely, there are shared principles of treatment. Emollients and topical agents are first line therapies; prednisolone, other systemic agents and biological agents may be effective in refractory cases. Conclusion: Clinical awareness of these skin reactions will enable early diagnosis, treatment, and improved outcomes.